The Biden administration issued final guidance for the second cycle of its landmark drug price negotiation program along with plans for implementing prices for the first two rounds.
The Centers for Medicare & Medicaid Services on Wednesday outlined its game plan for the second round of the Medicare Drug Price Negotiation Program, a program set up by the 2022 Inflation Reduction Act that allows the government to set the prices of some of the costliest and widely used drugs covered under Medicare.
The guidance comes after the government in August unveiled the negotiated prices for 10 Part D prescription drugs ...